RECALL: Fish sold in Connecticut recalled by FDA due to bacteria concerns
BRIDGEPORT, Conn. (WTNH) — Salted Smoked Split Herring sold in Connecticut is being recalled by the Food and Drug Administration (FDA).
Fungi concerns spark nationwide recall of Zicam and Orajel products
The recalled fish was distributed to retail locations in New York, New Jersey and Connecticut. Experts say that the product has potential to be contaminated with a bacteria called Clostridium botulinum that can cause life-threatening illness or death.
The product was likely to be repacked in deli-style or other retail packaging.
The fish is sold at Food Bazaar Supermarket in Bridgeport.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Meet the tree that could save Florida's citrus industry
Matt Mattia used both hands to flip through the branch at his eye level, studying each side of every leaf as sunlight filtered from above. 'Just healthy leaves,' he said, noting the dark green color. He turned his attention to a young fruit that was still the same color as the leaf next to it. 'That looks pretty symmetrical,' he said, plucking it for further examination. 'That should develop into a nice, big orange.' Mattia is no farmer, and the tree was no ordinary plant. He works for the United States Department of Agriculture as a geneticist. The tree has a name: Donaldson. Mattia called it the most researched tree in the state of Florida. It's also the tree that growers hope will save the state's citrus industry. 'When I saw the Donaldson tree, I was like, 'Wow, this is something that's really unique and really different,'' Mattia said. Donaldson's notoriety has come from its unique combination of three attributes: its status as a genetically pure orange tree, its sweet taste, and most importantly, its resistance to the Huanglongbing disease, more commonly known as HLB or 'greening.' Since arriving in the United States from Brazil, greening has killed groves across the state of Florida and contributed to a 90% decline in citrus production over the past 20 years. Leaves of infected trees appear splotchy in color and can be abnormally shaped. The tree's fruit also takes on irregular characteristics – until the tree dies. While it has infected almost every variety of citrus tree, it hit one of two types of orange trees particularly hard: the Hamlin variety, which fruits early in the winter before the late-season Valencia oranges came in. Under FDA rules, Hamlins and Valencias are the two major types of oranges that are allowed to be used for Florida orange juice, Mattia explained. Without the Hamlin trees, growers' profits suffered. Donaldson is also an early season tree. It was planted 30 years ago when the USDA created its Groveland research farm with different citrus varieties that growers could fall back on, like a seed bank. Mattia found it by sampling 25,000 different trees to test for infection and fruit sweetness. He found other trees tolerated greening, but their fruit was bitter, bordering on inedible, he recalled. Donaldson, with its high sugar content, stood out. A Hamlin tree was planted near Donaldson at the same time. Mattia pointed at the spot, which was nothing more than the remnant of a trunk sticking out of the ground and a pink ribbon tied around it. Greening did most of the damage, and Hurricane Milton finished it off, he said. 'It just was a huge stark contrast between something that was really very, very sick and declining and something that appears to continue to produce a regular crop,' he explained. 'We took the fruit, we sampled the fruit, and we tasted it, and we were like, wow, this has industry potential.' Now that they've settled on a tree, Mattia and his team have been figuring out what it would take to make Donaldson a commercial success. Several researchers analyzed the taste, which to the average palette is identical to Hamlin and Valencia. The best method to produce orange juice was also looked at, with Mattia opening a bottle that had been created using a method new to their research. Mattia's team is now working on the next phase of their testing: monitoring young Donaldsons that had been grafted onto dozens of different rootstocks to see which combination of plants grow the strongest and fastest. One Hamlin tree planted among the Donaldsons as a control showed signs of greening infection. Mattia said it was highly likely many of the healthy-looking nine-month-old plants had already been hit, though as a researcher it only helped him get further to his goal. But the USDA isn't gate-keeping Donaldson, even though the tree itself is grown behind fences and locks. 'We're pushing it out to commercial usage,' Mattia said. 'If people want to test it in their own grove, it's available, and we have the data and the research going on here that supports that effort.' Florida is already on-board. Mattia said the state has propagated 18,000 Donaldsons that it's sending to growers across the state to accelerate the adoption effort. One of those potentially interested is Mary Graham, owner of Graham's U-Pick Farms, who had heard of Donaldson and wanted to know how many seeds each fruit had (five to seven) and whether the fruit was edible when freshly picked (yes). For a century, Graham's specialized in oranges. As of this year, they only grow peaches. 'We noticed greening hitting our grove probably about 15 years ago,' she recalled. 'About 10, 12, years ago, it started getting a little more aggressive. So at that point, we looked for an alternative crop.' Like her neighbors, Graham tried different methods to save her trees. She and her husband added more nutrients to the soil and cut down on chemicals, which she said helped the trees recover. Eventually, the disease won the battle, and her husband tore out the last of the trees in January. She's looking to plant new seedlings for her children to eventually care for, even though she said her peaches were better for business. 'We're hopeful about the Donaldson tree,' she said. 'With that one, what else can they come up with?' That's what Mattia is all about. He previewed 'future orange juice,' a blend of different citrus fruits that resembles orange juice but has a notable flavor difference that's being created as an alternative to Donaldson in case the tree doesn't work out. 'My mission is to really help people,' he said. 'So if they, if the industry and the processors find utility from this tree, I feel like our mission is accomplished.' Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.
Associated Press
2 hours ago
- Associated Press
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older. 'RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'We appreciate the FDA's review and thank all the participants in our clinical trial as well as the Moderna team for their dedication to protecting people against RSV.' While the risk of RSV is well recognized in infants and older adult populations, adults aged 18-59 years with chronic conditions are also vulnerable.1 Over one-third of adults aged 18-59 years have at least one underlying condition that puts them at increased risk of severe RSV disease,2 with disease burden and hospitalization rates in this population being comparable, or even exceeding, that observed in older adults.3 This approval was supported by results from Moderna's Phase 3 study ( NCT06067230 ), which evaluated the safety and immunogenicity of mRESVIA in adults aged 18-59 with underlying health conditions. The immune responses against both RSV-A and RSV-B met prespecified non-inferiority immunobridging criteria when compared to those observed in adults aged 60 years and older in the pivotal Phase 3, placebo-controlled safety and efficacy study. Comparable levels of neutralizing antibodies were observed across both the 18-49 and 50-59 age subgroups, supporting the vaccine's consistent immunogenicity profile in this at-risk, younger adult population. These findings were presented at the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) meeting in April 2025 and have been published in Clinical Infectious Diseases. The vaccine was generally well-tolerated, and the most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia. Moderna intends to have mRESVIA available for both younger adults at increased risk (ages 18-59) and older adults (ages 60+) in the U.S. for the 2025-2026 respiratory virus season. About mRESVIA® (Respiratory Syncytial Virus Vaccine) mRESVIA® is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna COVID-19 vaccines. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. mRESVIA® is a registered trademark of Moderna. INDICATION mRESVIA is a vaccine to protect you against lower respiratory tract disease caused by Respiratory Syncytial Virus (RSV). mRESVIA is for people 60 years of age and older and also for people 18 through 59 years of age who are at increased risk for RSV (people with medical conditions such as diabetes or with diseases affecting the lungs and heart). Vaccination with mRESVIA may not protect all people who receive the vaccine. mRESVIA does not contain RSV. mRESVIA cannot give you lower respiratory tract disease caused by RSV. IMPORTANT SAFETY INFORMATION Who should not get mRESVIA? You should not get mRESVIA if you had a severe allergic reaction to any ingredient in mRESVIA. What should you tell your healthcare provider? Tell your healthcare provider about all of your medical conditions, including if you: How is mRESVIA given? mRESVIA is given as an injection into the muscle. What are the risks of mRESVIA? There is a very small chance that mRESVIA could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of mRESVIA. For this reason, your healthcare provider may ask you to stay for a short time at the place where you received your vaccine. Signs of a severe allergic reaction may include: Side effects that have been reported in clinical trials with mRESVIA include: These may not be all of the possible side effects of mRESVIA. Ask your healthcare provider about any side effects that concern you. You may report side effects to the Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or Please click for mRESVIA Full Prescribing Information. Moderna Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the efficacy, safety and tolerability of mRESVIA; the disease burden associated with RSV, particularly in adults with certain risk factors; and the availability of mRESVIA for the 2025-2026 season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Media: Chris Ridley Head of Global Media Relations +1 617-800-3651 [email protected] Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 [email protected] 1 Prasad N, Walker TA, Waite B, et al. Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions. Clin Infect Dis 2021; 73(1): e158-e63. 2 Wilker E, Jiang M, Francis B, et al. Burden of chronic medical conditions that are risk factors for severe RSV among adults aged 18-59 years in the United States. Poster presented at: ESCMID; April 2025; Vienna, Austria. 3 Weycker D, Averin A, Houde L, et al. Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile. Infect Dis Ther 2024; 13(1): 207-20. SOURCE: Moderna, Inc. press release
USA Today
2 hours ago
- USA Today
Over 44,000 pounds of Bornstein Seafoods shrimp recalled over listeria concerns
Over 44,000 pounds of Bornstein Seafoods shrimp recalled over listeria concerns Show Caption Hide Caption Cucumbers under recall Cucumbers grown in Florida are part of the latest salmonella outbreak. The FDA issued a recall after the cucumbers were linked to Bedner Growers. Fox - 13 News A Washington-based seafood company voluntarily recalled over 44,000 pounds of ready-to-eat shrimp meat over possible contamination with Listeria monocytogenes. The recall was the result of a "routine sampling program" conducted by the company, Bornstein Foods. "Listeria monocytogenes was detected in an in-process shrimp sample in a food production environment," Bornstein Foods said in a June 10 notice from the Food & Drug Administration. "The company has ceased the distribution of the product as the company continues our root cause investigation as to what caused the problem." The affected products were sold directly to distributors and retailers in three states, including California, Oregon and Washington, as well as British Columbia of Canada, according to the notice. Bornstein Seafoods, headquartered in Bellingham, Washington, noted in its advisory that the "products may have been further distributed and sold at retailers nationwide." It's not immediately clear which, or how many distributors or retailers were sold this product. No illnesses have been reported in connection with this recall. When contacted by USA TODAY, Bornstein Seafoods referred any questions back to the FDA's notice. Bornstein Seafoods recall: See affected products The easiest way for consumers to check if they have purchased and are in possession of the affected product is by verifying if the product details we share match the bag, or bags you have. Here are some things to look for: Product name: Bornstein Seafoods brand "Cooked & Peeled Ready-To-Eat Coldwater Shrimp Meat" Bornstein Seafoods brand "Cooked & Peeled Ready-To-Eat Coldwater Shrimp Meat" Product information: 1 lb and 5 lb bags may be affected Relevant Lot Codes, Item Numbers, Universal Product Codes and Master Case Label Description are listed here. The affected product has the lot code printed at the lower left corner of master case label and at the bottom on the back side of the 1 pound or 5 pound bag. What should I do if I have the recalled shrimp meat? Consumers who have purchased the affected product are urged to return it to the place of purchase for a full refund. Consumers with questions may contact the company via email at Andrew@
